TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search results
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search resultsTalks continue for Bio Farma-Pfizer vaccine partnership
Coordinating Maritime Affairs and Investment Minister Luhut Pandjaitan said on Tuesday that the US had said that it was willing to help Indonesia on COVID-19 vaccine development.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
T
he Indonesian government is in talks with the United States government to form a partnership between state-owned pharmaceutical holding firm PT Bio Farma and US company Pfizer Inc to develop a COVID-19 vaccine, a state official has said.
Coordinating Maritime Affairs and Investment Minister Luhut Pandjaitan said on Tuesday that the US had said that it was willing to help Indonesia on COVID-19 vaccine development.
“[US] Vice President [Mike] Pence and I talked for 15 minutes [during my visit to the US] about the vaccine and they are willing to help us with the development,” he said during his speech at the 2020 CEO Networking virtual event.
He also said that Deputy State-Owned Enterprises Minister Budi Gunadi Sadikin held discussions with the US Health Secretary Office and the Indonesian Food and Drug Monitoring Agency (BPOM) to follow up on the talk.
“We followed up the discussion through video call last night to partner Bio Farma with Pfizer on the vaccine development,” said Luhut.
Read also: G-20 to commit to fair access to COVID-19 vaccine
Pfizer announced on Nov. 9 that its experimental COVID-19 vaccine, developed along with its German partner BioNTech SE, was more than 90 percent effective based on initial trial results. It is expected to seek US emergency use authorization this month.
